Table 2.
Relationships between general symptoms of COVID-19 in terms of severity, duration, and the frequency and presence of oral manifestations of COVID-19.
| Symptom | Total 195 |
Severity of Specific COVID-19 Symptom | Duration of Specific COVID-19 Symptom | Frequency of Specific COVID-19 Symptom | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mild | Moderate | Severe | p-Value | 1–2 Days | 3–4 Days | 5+ Days | p-Value | Once | Intermittent | Constant | p-Value | ||
| Fever | 140 (72%) | 34 (24%) | 81 (58%) | 25 (18%) | 47 (35%) | 46 (35%) | 40 (30%) | 13 (11%) | 65 (53%) | 45 (36%) | |||
| Oral manifestations + | 43 (31%) | 9 (26%) | 30 (37%) | 4(16%) | 0.8751 | 15 (32%) | 13 (28%) | 14 (35%) | 0.7971 | 5 (39%) | 22 (34%) | 11 (24%) | 0.4745 |
| Oral manifestations − | 97 (69%) | 25 (74%) | 51 (68%) | 21 (84%) | 32 (68%) | 33 (72%) | 26 (65%) | 8 (62%) | 43 (66%) | 34 (76%) | |||
| Headache | 127 (65%) | 33 (24%) | 42 (33%) | 52 (41%) | 25 (22%) | 29 (25%) | 61 (53%) | 10 (9%) | 55 (49%) | 47 (42%) | |||
| Oral manifestations + | 38 (29%) | 11 (33%) | 12 (29%) | 15 (28%) | 0.8832 | 6 (24%) | 9 (31%) | 20 (33%) | 0.7214 | 0 (0%) | 22 (40%) | 22 (40%) | 0.0336 |
| Oral manifestations − | 89 (71%) | 22 (67%) | 30 (71%) | 37 (72%) | 19 (76%) | 20 (69%) | 41 (67%) | 10 (100%) | 33 (60%) | 34 (72%) | |||
| Fatigue | 126 (65%) | 33 (26%) | 48 (38%) | 45 (36%) | 19 (16%) | 36 (31%) | 61 (53%) | 3 (3%) | 37 (34%) | 69 (63%) | |||
| Oral manifestations + | 40 (32%) | 13 (39%) | 17 (35%) | 10 (22%) | 0.2151 | 2 (11%) | 7 (19%) | 30 (49%) | 0.0007 | 0 (0%) | 13 (35%) | 22 (32%) | 0.4548 |
| Oral manifestations − | 86 (68%) | 20 (61%) | 31 (65%) | 35 (78%) | 17 (89%) | 29 (82%) | 31 (51%) | 3 (100%) | 24 (65%) | 47 (68%) | |||
| Cough | 122 (63%) | 41 (34%) | 49 (40%) | 32 (26%) | 19 (17%) | 29 (25%) | 66 (58%) | 5 (5%) | 56 (55%) | 41 (40%) | |||
| Oral manifestations + | 39 (32%) | 17 (42%) | 16 (33%) | 6 (19%) | 0.1176 | 3 (16%) | 12 (41%) | 23 (35%) | 0.1669 | 2 (40%) | 21 (38%) | 11 (27%) | 0.5188 |
| Oral manifestations − | 83 (68%) | 24 (58%) | 33 (67%) | 26 (81%) | 16 (84%) | 17 (59%) | 43 (65%) | 3 (60%) | 35 (62%) | 30 (73%) | |||
| Myalgia/arthralgia | 104 (53%) | 26 (25%) | 37 (36%) | 41 (39%) | 18 (19%) | 24 (26%) | 52 (55%) | 6 (54%) | 36 (40%) | 49 (6%) | |||
| Oral manifestations + | 32 (31%) | 11 (42%) | 13 (35%) | 8 (20%) | 0.1111 | 3 (17%) | 8 (33%) | 20 (38%) | 0.2375 | 0 (0%) | 16 (44%) | 15 (31%) | 0.0736 |
| Oral manifestations − | 72 (69%) | 15 (58%) | 24 (65%) | 33 (80%) | 15 (83%) | 16 (67%) | 32 (62%) | 6 (100%) | 20 (56%) | 34 (69%) | |||
| Loss of smell | 102 (53%) | 9 (9%) | 19 (19%) | 74 (72%) | 5 (5%) | 8 (9%) | 80 (86%) | 1 (1%) | 4 (5%) | 78 (94%) | |||
| Oral manifestations + | 40 (39%) | 5 (55%) | 10 (53%) | 25 (34%) | 0.1865 | 1 (20%) | 7 (88%) | 31 (39%) | 0.0122 | 0 (0%) | 2 (50%) | 33 (42%) | 1.0000 |
| Oral manifestations − | 62 (61%) | 4 (44%) | 9 (47%) | 49 (66%) | 4 (80%) | 1 (12%) | 49 (61%) | 1 (100%) | 2 (50%) | 45 (58%) | |||
| Sore throat | 97 (50%) | 33 (34%) | 38 (39%) | 26 (27%) | 18 (20%) | 39 (44%) | 32 (36%) | 9 (11%) | 27 (33%) | 47 (56%) | |||
| Oral manifestations + | 34 (35%) | 14 (42%) | 10 (26%) | 10 (38%) | 0.3338 | 5 (28%) | 15 (38%) | 12 (38%) | 0.7181 | 2 (22%) | 11 (41%) | 17 (36%) | 0.6056 |
| Oral manifestations − | 63 (65%) | 19 (58%) | 28 (74%) | 16 (62%) | 13 (72%) | 24 (62%) | 20 (62%) | 7 (78%) | 26 (59%) | 30 (64%) | |||
| Dyspnea | 78 (40%) | 22 (28%) | 24 (31%) | 32 (41%) | 10 (15%) | 22 (32%) | 36 (53%) | 8 (12%) | 35 (54%) | 22 (34%) | |||
| Oral manifestations + | 22 (28%) | 8 (36%) | 7 (29%) | 7(22%) | 0.5048 | 2 (20%) | 8 (36%) | 11 (31%) | 0.6485 | 2 (25%) | 13 (37%) | 5 (23%) | 0.4818 |
| Oral manifestations − | 56 (72%) | 14 (64%) | 17 (71%) | 25 (78%) | 8 (80%) | 14 (64%) | 25 (69%) | 6 (75%) | 22 (67%) | 17 (77%) | |||
|
Nausea/
vomiting |
41 (21%) | 20 (49%) | 15 (36%) | 6 (15%) | 11 (34%) | 7 (22%) | 14 (44%) | 5 (13%) | 22 (71%) | 4 (16%) | |||
| Oral manifestations + | 11 (27%) | 5 (25%) | 5 (33%) | 1 (17%) | 0.7991 | 1 (9%) | 3 (43%) | 5 (36%) | 0.2099 | 2 (40%) | 6 (27%) | 1 (25%) | 0.8367 |
| Oral manifestations − | 30 (73%) | 15 (75%) | 10 (67%) | 5 (83%) | 10 (91%) | 4 (57%) | 9 (64%) | 3 (60%) | 16 (73%) | 3 (75%) | |||
| Diarrhea | 30 (15%) | 19 (63%) | 8 (27%) | 3 (10%) | 13 (57%) | 4 (17%) | 6 (26%) | 6 (29%) | 11 (52%) | 4 (19%) | |||
| Oral manifestations + | 11 (37%) | 7 (37%) | 4 (50%) | 0 (0%) | 0.3861 | 6 (46%) | 1 (25%) | 2 (33%) | 0.7085 | 4 (67%) | 3 (27%) | 1 (25%) | 0.2329 |
| Oral manifestations − | 19 (63%) | 12 (63%) | 4 (50%) | 3 (100%) | 7 (54%) | 3 (75%) | 4 (67%) | 2 (33%) | 8 (73%) | 3 (75%) | |||
Oral manifestations +: Patient(s) developed oral manifestations of COVID-19 simultaneously with having the general symptom listed just above it. Oral manifestations −: Patient(s) did not have oral manifestations of COVID-19 simultaneously with the general symptom listed above it.